29-Nov-2019 | Zion Market Research
Zion Market Research has published a new report titled “Macular Degeneration Treatment Market by Drug Class (Anti-VEGFs and Other Drugs); by Indication (Wet Age-related Macular Degeneration (wAMD) and Dry Age-related Macular Degeneration (dAMD)); by Distribution Channel (Ambulatory Surgical Centers, Ophthalmic Clinics and Hospitals): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 – 2025”. According to the report, global demand for macular degeneration treatment market was valued at approximately USD 6.38 billion in 2018, and is expected to generate revenue of around USD 10.07 billion by end of 2025, growing at a CAGR of around 6.8% between 2019 and 2025.
Browse the full “Macular Degeneration Treatment Market: by Drug Class (Anti-VEGFs and Other Drugs); by Indication (Wet Age-related Macular Degeneration (wAMD) and Dry Age-related Macular Degeneration (dAMD)); by Distribution Channel (Ambulatory Surgical Centers, Ophthalmic Clinics and Hospitals): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 - 2025” Report at https://www.zionmarketresearch.com/report/macular-degeneration-treatment-market
The study provides a crucial view on the macular degeneration treatment by segmenting the market based on.
Macular degeneration is an age related eye disorder that may lead to vision loss if left untreated. Macula is central portion of retina which is damaged whereas side portion remains unaffected in macular degeneration (MD). Fine details cannot be visualized even if the object is close or far. Macular degeneration is incurable however current treatment aims to prevent or control serious complications like vision loss.
Macular degeneration treatment market is witnessing robust growth due to various factors such as increasing aging population across the globe, growing prevalence of eye disorders and age related macular degeneration. This growth is further supported by increasing health awareness, government initiatives to support R&D, emphasis of pharmaceutical players on development of novel treatment options, and increasing healthcare spending. However, increase in off-label use of products may impede the market growth. Emerging countries with increasing elderly population with high prevalence of age related macular degeneration (AMD) and high unmet medical needs are factors that are projected to open new growth avenues for market players operating in the global macular degeneration treatment.
Market for macular degeneration is segmented based on indication, drug class, distribution channel and region. Based on drug class, market is categorized into anti-VEGFs (anti-vascular endothelial growth factor), and other drugs. Market was dominated by anti-VEGFs in 2018. For macular degeneration treatment, anti-VEGFs are assumed to be gold standard and it is projected that anti-VEGFs will see rapid growth in the coming years.
Based on indication, macular degeneration market is segmented into wAMD (wet age-related macular degeneration) and dAMD (dry age-related macular degeneration). Dry age-related macular degeneration segment dominated the market with largest revenue share in 2018 owing to increasing prevalence and increasing ongoing research projects for novel treatment development for dAMD. Wet age-related macular degeneration is more aggressive form of AMD and leads to faster central vision loss. wAMD segment is projected to register highest growth in the forecast period. Favorable reimbursement policies are projected to support this growth in the coming years.
Ambulatory surgical centers, hospitals and ophthalmic clinics are different types of distribution channels for macular degeneration market. Hospitals held the largest revenue share of macular degeneration treatment market. Easy accessibility and availability of advanced facilities in the hospitals are major factors supporting the growth of this segment. Ophthalmic clinics are anticipated to register rapid growth during the forecast period.
At regional level, North America accounted for largest market share of the global macular degeneration treatment market in 2018. Growing occurrence of eye disorders, favorable reimbursement policies, increasing elderly population and growing awareness are factors driving the market in this region. Europe was second largest regional market. Increasing health awareness, availability of advanced health facilities, increasing prevalence of eye disorders are market driving factors in this region. Latin America is projected to witness moderate growth over the forecast period. Asia Pacific region is projected to witness highest growth for macular degeneration treatment market in the coming years. Increasing elderly population with high prevalence of age related macular degeneration, growth in health care spending, increasing disposable income and growing awareness are factors promoting macular degeneration treatment market growth in Asia Pacific. Middle East and Africa is projected to register moderate growth in coming years.
Major players included in the report are Santen Pharmaceuticals, Valeant Pharmaceuticals, Sanofi, Pfizer, Inc., StemCells, F. Hoffmann-La Roche, Ophthotech Corporation, Neurotech Pharmaceuticals, GlaxoSmithKline, Bayer AG, Novartis AG and Allergan among others.
The report segment of global macular degeneration treatment market as follows:
Global Macular Degeneration Treatment Market: By Drug Class
Global Macular Degeneration Treatment Market: By Indication
Global Macular Degeneration Treatment Market: By Distribution Channel
Global Macular Degeneration Treatment Market: By Region
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651